Document is current

Article History

Accepted: 20 February 2025

First Online: 25 March 2025

Declarations

:

: Conceptualization and Literature Review: RG, KL, JLH. Writing and critical review of the manuscript: RG, KL, ABC, VYS, JLH. All authors have read and approved the final version of this manuscript.

: Open access funding provided by SCELC, Statewide California Electronic Library Consortium. No funding was received for the preparation of this article.

: Katrina Lee has served as an investigator for Novartis. Ashley B. Crew has served as an investigator for Incyte and AstraZeneca. Vivian Y. Shi is on the board of directors for the Hidradenitis Suppurativa Foundation, an advisor for the National Eczema Association, is a stock shareholder of Learn Health, and has served as an advisory board member, investigator, speaker, and/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Genentech, Eli Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Dermavant, Boehringer Ingelheim, Almirall, Alumis, Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt’s Bees, Galderma, Kiniksa, UCB, Ceraclere, Bain Capital, Target-PharmaSolutions, Castle Bioscience, Altus Lab/cQuell, MYOR, Polyfins Technology, GpSkin, and Skin Actives Scientific. Jennifer L. Hsiao is on the board of directors for the Hidradenitis Suppurativa Foundation, and has served as an advisor, investigator, and/or speaker for AbbVie, Aclaris, AstraZeneca, Boehringer Ingelheim, Galderma, Incyte, Novartis, Pfizer, Regeneron, Sanofi, and UCB. Raveena Ghanshani has no conflicts of interest that are directly relevant to the content of this article.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.